6-bromo-1H-indole-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester | 1440807-02-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-bromo-1H-indole-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester
• 英文别名: 1-(tert-butyl) 4-methyl 6-bromo-1H-indole-1,4-dicarboxylate；1-O-tert-butyl 4-O-methyl 6-bromoindole-1,4-dicarboxylate
• CAS: 1440807-02-2
• 化学式: C₁₅H₁₆BrNO₄
• 分子量: 354.2
• InChiKey: IGNOOYDYYHQTEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-bromo-1H-indole-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester 在 二氧化碳 、 偶氮二甲酸二异丙酯 、 二异丁基氢化铝 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 正庚烷 、 二氯甲烷 、 异丙醇 为溶剂， 反应 5.0h， 生成 2-[3-(6-bromo-1H-indol-4-ylmethyl)-2-oxo-2,3-dihydrobenzoimidazol-1-ylmethyl]pentanoic acid ethyl ester
  参考文献：
  名称：

  Discovery of Potent, Selective Chymase Inhibitors via Fragment Linking Strategies

  摘要：

  Chymase plays an important and diverse role in the homeostasis of a number of cardiovascular processes. Herein, we describe the identification of potent, selective chymase inhibitors, developed using fragment-based, structure-guided linking and optimization techniques. High-concentration biophysical screening methods followed by high-throughput crystallography identified an oxindole fragment bound to the S1 pocket of the protein exhibiting a novel interaction pattern hitherto not observed in chymase inhibitors. X-ray crystallographic structures were used to guide the elaboration/linking of the fragment, ultimately leading to a potent inhibitor that was >100-fold selective over cathepsin G and that mitigated a number of liabilities associated with poor physicochemical properties of the series it was derived from.

  DOI：

  10.1021/jm400138z
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 6-溴-4-吲哚甲酸甲酯 在 4-二甲氨基吡啶 作用下， 以 乙腈 为溶剂， 反应 16.17h， 以99%的产率得到6-bromo-1H-indole-1,4-dicarboxylic acid 1-tert-butyl ester 4-methyl ester
  参考文献：
  名称：

  Discovery of Potent, Selective Chymase Inhibitors via Fragment Linking Strategies

  摘要：

  Chymase plays an important and diverse role in the homeostasis of a number of cardiovascular processes. Herein, we describe the identification of potent, selective chymase inhibitors, developed using fragment-based, structure-guided linking and optimization techniques. High-concentration biophysical screening methods followed by high-throughput crystallography identified an oxindole fragment bound to the S1 pocket of the protein exhibiting a novel interaction pattern hitherto not observed in chymase inhibitors. X-ray crystallographic structures were used to guide the elaboration/linking of the fragment, ultimately leading to a potent inhibitor that was >100-fold selective over cathepsin G and that mitigated a number of liabilities associated with poor physicochemical properties of the series it was derived from.

  DOI：

  10.1021/jm400138z

文献信息

• [EN] SUBSTITUTED INDOLE MCL-1 INHIBITORS<br/>[FR] INHIBITEURS DE INDOLE MCL-1 SUBSTITUÉS
  申请人：UNIV VANDERBILT

  公开号：WO2015148854A1

  公开（公告）日：2015-10-01

  The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.

  本发明提供了一种抑制抗凋亡Bcl-2家族成员髓细胞白血病-1 (Mcl-1)蛋白活性的化合物。本发明还提供了用于治疗因Mcl-1蛋白过度表达或失调而表征的疾病和病况（例如癌症）的药物组合物以及使用化合物的方法。
• SUBSTITUTED INDOLE MCL-1 INHIBITORS
  申请人：Vanderbilt University

  公开号：US20170174689A1

  公开（公告）日：2017-06-22

  The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.

  本发明提供了一种抑制抗凋亡Bcl-2家族成员髓性细胞白血病-1（Mcl-1）蛋白活性的化合物。本发明还提供了药物组合物以及使用化合物治疗由于Mcl-1蛋白过度表达或失调而导致的疾病和病况（例如癌症）的方法。
• Isoxazole derivatives as nuclear receptor agonists and uses thereof
  申请人：IL DONG PHARMACEUTICAL CO., LTD.

  公开号：US10988449B2

  公开（公告）日：2021-04-27

  The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).

  本发明涉及异噁唑衍生物，包括药物组合物和异噁唑衍生物的制备方法。更具体地说，本发明提供了一种异噁唑衍生物的药物组合物，用于激活法尼类固醇 X 受体（FXR，NR1H4）。
• Substituted indole Mcl-1 inhibitors
  申请人：Vanderbilt University

  公开号：US11208415B2

  公开（公告）日：2021-12-28

  The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.

  本发明提供了抑制抗凋亡 Bcl-2 家族成员骨髓细胞白血病-1（Mcl-1）蛋白活性的化合物。本发明还提供了药物组合物以及使用化合物治疗以 Mcl-1 蛋白过度表达或失调为特征的疾病和病症（如癌症）的方法。
• ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF
  申请人：IL DONG PHARMACEUTICAL CO., LTD.

  公开号：US20200115349A1

  公开（公告）日：2020-04-16

  The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).